F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2016

F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2016


  • Products Id :- GMDHC07982CDB
  • |
  • Pages: 327
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'F. Hoffmann-La Roche Ltd.-Product Pipeline Review-2016', provides an overview of the F. Hoffmann-La Roche Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by F. Hoffmann-La Roche Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of F. Hoffmann-La Roche Ltd.

The report provides overview of F. Hoffmann-La Roche Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses F. Hoffmann-La Roche Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features F. Hoffmann-La Roche Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate F. Hoffmann-La Roche Ltd.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for F. Hoffmann-La Roche Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding F. Hoffmann-La Roche Ltd.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

F. Hoffmann-La Roche Ltd. Snapshot 7

F. Hoffmann-La Roche Ltd. Overview 7

Key Information 7

Key Facts 7

F. Hoffmann-La Roche Ltd.-Research and Development Overview 8

Key Therapeutic Areas 8

F. Hoffmann-La Roche Ltd.-Pipeline Review 18

Pipeline Products by Stage of Development 18

Pipeline Products-Monotherapy 19

Pipeline Products-Combination Treatment Modalities 20

Pipeline Products-Partnered Products 21

Pipeline Products-Out-Licensed Products 24

F. Hoffmann-La Roche Ltd.-Pipeline Products Glance 26

F. Hoffmann-La Roche Ltd.-Late Stage Pipeline Products 26

F. Hoffmann-La Roche Ltd.-Clinical Stage Pipeline Products 29

F. Hoffmann-La Roche Ltd.-Early Stage Pipeline Products 33

F. Hoffmann-La Roche Ltd.-Drug Profiles 36

alectinib 36

atezolizumab 38

bevacizumab 43

obinutuzumab 50

omalizumab 54

rituximab 56

alteplase 60

emicizumab 61

gantenerumab 62

idasanutlin 64

lebrikizumab 66

ocrelizumab 68

onartuzumab 70

pertuzumab 73

ranibizumab 77

tocilizumab 81

trastuzumab emtansine 85

vemurafenib 89

olesoxime 93

(danoprevir + ritonavir) 96

basimglurant 97

basmisanil 99

cobimetinib fumarate 100

codrituzumab 105

danoprevir 106

emactuzumab 108

miravirsen 109

RG-7314 111

RG-7716 112

RG-7795 113

RG-7800 115

RO-5093151 116

RO-6864018 117

TRX-1 118

vanucizumab 119

RG-6016 120

cergutuzumab amunaleukin 122

DCDS-0780A 123

lumretuzumab 124

OP-0595 126

PRX-002 127

RG-4929 128

RG-6061 129

RG-6069 131

RG-6078 132

RG-6125 133

RG-7304 135

RG-7386 136

RG-7461 137

RG-7625 138

RG-7775 139

RG-7802 140

RG-7834 141

RG-7876 142

RG-7880 143

RG-7916 144

RG-7944 145

RG-7986 147

RG-7992 148

RO-6799477 149

RO-6806127 150

RO-6836191 151

RO-6870868 152

RO-6874281 153

RO-6874813 154

RO-6889678 155

RO-7020322 156

RO-7033877 157

vismodegib 158

Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases 162

CLP-257 163

GAL-F2 164

Gene Therapy to Activate Telomerase for Aplastic Anemia 165

IMA-930 166

IMA-942 167

IMA-962 168

ITMN-10534 169

ITMN-14440 170

ITMN-30162 171

Monoclonal Antibody Conjugates for Solid Tumor 172

Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections 173

Monoclonal Antibody to Inhibit VEGF-A for Ophthalmology 174

RN-486 175

RO-2959 176

RO-4938581 177

RO-5073012 178

RO-5203280 179

RO-5461111 180

RO-646198 181

RO-6839328 182

RO-6889450 183

RO-9021 184

Small Molecule 2 to Inhibit XIAP for Oncology 185

Small Molecule to Agonize GPR119 for Type II Diabetes 186

Small Molecule to Inhibit XIAP for Oncology 187

Small Molecules for Myotonic Dystrophy Type 1 188

Small Molecules to Inhibit ERG for Prostate Cancer 190

Small Molecules to Inhibit Janus Kinase 3 for Inflammation 191

Small Molecules to Inhibit PTP1B for Obesity and Diabetes 192

Small Molecules to Inhibit Viral RNA Polymerase for Influenza 193

XGFR-2 194

XGFR-4 195

Monoclonal Antibodies for Cancer 196

RG-7109 197

RO-5454948 198

RO-8994 199

Small Molecule to Activate Glycogen Synthase for Type 2 Diabetes 200

Small Molecule to Inhibit LOXL2 for Fibrosis 201

Small Molecule to Inhibit NS5B for Hepatitis C 202

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections 203

Small Molecules for Neuropsychiatric Disorders 204

Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis 205

F. Hoffmann-La Roche Ltd.-Pipeline Analysis 206

F. Hoffmann-La Roche Ltd.-Pipeline Products by Target 206

F. Hoffmann-La Roche Ltd.-Pipeline Products by Route of Administration 212

F. Hoffmann-La Roche Ltd.-Pipeline Products by Molecule Type 213

F. Hoffmann-La Roche Ltd.-Pipeline Products by Mechanism of Action 214

F. Hoffmann-La Roche Ltd.-Recent Pipeline Updates 218

F. Hoffmann-La Roche Ltd.-Dormant Projects 283

F. Hoffmann-La Roche Ltd.-Discontinued Pipeline Products 288

F. Hoffmann-La Roche Ltd.-Discontinued Pipeline Products 288

Discontinued Pipeline Product Profiles 290

F. Hoffmann-La Roche Ltd.-Company Statement 305

F. Hoffmann-La Roche Ltd.-Locations And Subsidiaries 307

Head Office 307

Other Locations & Subsidiaries 308

Appendix 316

Methodology 316

Coverage 316

Secondary Research 316

Primary Research 316

Expert Panel Validation 316

Contact Us 316

Disclaimer 317

List of Figures

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Indication, 2016 19

F. Hoffmann-La Roche Ltd.-Pipeline by Stage of Development, 2016 28

F. Hoffmann-La Roche Ltd.-Monotherapy Products in Pipeline, 2016 29

F. Hoffmann-La Roche Ltd.-Partnered Products in Pipeline, 2016 31

F. Hoffmann-La Roche Ltd.-Out-Licensed Products in Pipeline, 2016 34

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Target, 2016 216

F. Hoffmann-La Roche Ltd.-Pipeline by Route of Administration, 2016 222

F. Hoffmann-La Roche Ltd.-Pipeline by Top 10 Molecule Type, 2016 223

F. Hoffmann-La Roche Ltd.-Pipeline Products by Top 10 Mechanism of Action, 2016 224

List of Tables

F. Hoffmann-La Roche Ltd., Key Information 17

F. Hoffmann-La Roche Ltd., Key Facts 17

F. Hoffmann-La Roche Ltd.-Pipeline by Indication, 2016 19

F. Hoffmann-La Roche Ltd.-Pipeline by Stage of Development, 2016 28

F. Hoffmann-La Roche Ltd.-Monotherapy Products in Pipeline, 2016 29

F. Hoffmann-La Roche Ltd.-Combination Treatment Modalities in Pipeline, 2016 30

F. Hoffmann-La Roche Ltd.-Partnered Products in Pipeline, 2016 31

F. Hoffmann-La Roche Ltd.-Partnered Products/ Combination Treatment Modalities, 2016 32

F. Hoffmann-La Roche Ltd.-Out-Licensed Products in Pipeline, 2016 34

F. Hoffmann-La Roche Ltd.-Out-Licensed Products/ Combination Treatment Modalities, 2016 35

F. Hoffmann-La Roche Ltd.-Pre-Registration, 2016 36

F. Hoffmann-La Roche Ltd.-Filing rejected/Withdrawn, 2016 37

F. Hoffmann-La Roche Ltd.-Phase III, 2016 38

F. Hoffmann-La Roche Ltd.-Phase II, 2016 39

F. Hoffmann-La Roche Ltd.-Phase I, 2016 41

F. Hoffmann-La Roche Ltd.-Preclinical, 2016 43

F. Hoffmann-La Roche Ltd.-Discovery, 2016 45

F. Hoffmann-La Roche Ltd.-Pipeline by Target, 2016 216

F. Hoffmann-La Roche Ltd.-Pipeline by Route of Administration, 2016 222

F. Hoffmann-La Roche Ltd.-Pipeline by Molecule Type, 2016 223

F. Hoffmann-La Roche Ltd.-Pipeline Products by Mechanism of Action, 2016 224

F. Hoffmann-La Roche Ltd.-Recent Pipeline Updates, 2016 228

F. Hoffmann-La Roche Ltd.-Dormant Developmental Projects,2016 293

F. Hoffmann-La Roche Ltd.-Discontinued Pipeline Products, 2016 298

F. Hoffmann-La Roche Ltd., Subsidiaries 318

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of F. Hoffmann-La Roche Ltd.; F. Hoffmann-La Roche Ltd. - Key Therapeutics; F. Hoffmann-La Roche Ltd. - Pipeline Overview and Promising Molecules; F. Hoffmann-La Roche Ltd. - News; F. Hoffmann-La Roche Ltd. - Latest Updates; F. Hoffmann-La Roche Ltd. - Pipeline; F. Hoffmann-La Roche Ltd. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 96390
Site License
USD 3000 INR 192780
Corporate User License
USD 4500 INR 289170

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com